{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-016427","form_type":"8-K","ticker":"MD","cik":"0000893949","company_name":"Pediatrix Medical Group, Inc.","filed_at":"2023-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.684487+00:00","generated_at":"2026-06-16T04:23:59.962415+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pediatrix Q1 net rev $491M, GAAP EPS $0.17, adj EPS $0.23, reaffirms FY adj EBITDA $235-245M","bullets":["Net revenue $491M, up 1.8% YoY; same-unit revenue up 2.0% driven by volume and collections.","GAAP EPS $0.17; adjusted EPS $0.23; prior year adjusted EPS $0.33 (incl $0.07 CARES benefit).","Adjusted EBITDA $40.1M vs $50.7M YoY; FY 2023 guidance reaffirmed at $235-245M.","Cash used in ops $100.6M; total debt $752M; share count decreased due to 2022 buybacks.","No CARES Act revenue recorded in Q1 2023 vs $10.4M in Q1 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-016427","json":"https://secwatch.observer/filing/0000950170-23-016427.json","markdown":"https://secwatch.observer/filing/0000950170-23-016427.md","text":"https://secwatch.observer/filing/0000950170-23-016427.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/893949/000095017023016427/0000950170-23-016427-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/893949/000095017023016427/md-20230502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T04:23:59.962415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"58e3c7aee478ad2cfc5bcfd444e7d98e7bcbdad8","claim":"Pediatrix Medical Group, Inc. reported the three months ended March 31, 2023 results: revenue $491 million, net income $14 million, EPS $0.17 per share.","evidence_excerpt":"Pediatrix Medical Group, Inc. (NYSE: MD) , the nation’s leading provider of highly specialized health care for women, children and babies , today reported earnings from continuing operations of $0.17 per share for the three months ended March 31, 2023. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.23. For the 2023 first quarter, Pediatrix reported the following results from continuing operations: • Net revenue of $491 million; • Income from continuing operations of $14 million; and • Adjusted EBITDA of $40 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/893949/000095017023016427/0000950170-23-016427-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Revenue","value":"$491 million"},{"label":"Net income","value":"$14 million"},{"label":"EPS","value":"$0.17 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}